CFCyril Fisher

Cyril Fisher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cyril Fisher has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    How we do it: a method of neck dissection for histopathological analysis

    by Tahwinder Upile, Waseem Jerjes, Seyed Ahmad Reza Nouraei, Sandeep Singh, Peter Clarke, Peter Rhys-Evans, Colin Hopper, David Howard, Anthony Wright, Holger Sudhoff, et al.

    Dissection of the lymphatic structures in the neck is an integral part of the management of many head and neck cancers.


  • Open Access

    Recent technological developments: in situ histopathological interrogation of surgical tissues and resection margins

    by Tahwinder Upile, Cyril Fisher, Waseem Jerjes, Mohammed El Maaytah, Sandeep Singh, Holger Sudhoff, Adam Searle, Daniel Archer, Leslie Michaels, Colin Hopper, et al.


  • Open Access

    Small bowel gastrointestinal stromal tumours and ampullary cancer in Type 1 neurofibromatosis

    by Kasim A Behranwala, Duncan Spalding, Andrew Wotherspoon, Cyril Fisher, Jeremy N Thompson

    Type 1 neurofibromatosis (NF-1) is an autosomal dominant disorder with variable penetrance; approximately 50% of cases present as new mutations We report a case of a 56 year-old man with Von Recklinghausen's disease, carcinoma of the ampulla of Vater and incidental benign gastrointestinal stromal tumours of the jejunum. Coexistence between ampullary carcinoid, ectopic pancreatic tissue in the jejunum and neurofibroma of the jejunum in NF-1 has been previously described however; the association of synchronous carcinoma of the ampulla of Vater and gastrointestinal stromal tumour of the jejunum in NF-1 has not been previously reported.


  • Calponin and h‐caldesmon expression in synovial sarcoma; the use of calponin in diagnosis

    by C Fisher, E Montgomery, V Healy

    Aims:  To assess the frequency of expression and potential diagnostic utility of calponin and caldesmon in synovial sarcomas.Methods and results: Immunohistochemistry with antibodies to calponin and h‐caldesmon was undertaken in paraffin sections from 50 synovial sarcomas (19 biphasic and 31 monophasic, of which one biphasic and eight monophasic tumours had poorly differentiated areas), 10 each of malignant peripheral nerve sheath tumour (MPNST), solitary fibrous tumour (SFT), dermatofibrosarcoma (DFSP), Ewing's sarcoma (ES/PNET), and neuroblastoma, eight alveolar rhabdomyosarcomas, five adult fibrosarcomas and five carcinosarcomas. Nine of 19 biphasic synovial sarcomas were positive for calponin in spindle and glandular areas, nine in spindle cells only, and one in glands only. All monophasic synovial sarcomas and poorly differentiated areas expressed calponin; in monophasic tumours this was focally (29% of cases), moderately (39%), or diffusely (32%) positive and the poorly differentiated areas were usually moderately or diffusely positive. Four synovial sarcomas showed focal reactivity for h‐caldesmon. Calponin was found in 4/10 MPNST, 7/10 SFT, 4/10 DFSP, 3/5 fibrosarcomas and the spindle component of the carcinosarcomas. H‐caldesmon was weakly positive in 1/10 MPNST, 4/10 SFT, 0/10 DFSP, 0/5 fibrosarcomas and 1/5 carcinosarcomas (glands only). Both markers were negative in the other small round cell tumours.Conclusions: Calponin can be used as an additional marker for synovial sarcoma. Its absence argues against the diagnosis. The presence of calponin might be useful in distinguishing poorly differentiated synovial sarcoma from other small round cell tumours. H‐caldesmon is not helpful in diagnosis of synovial sarcoma.


  • Leiomyosarcoma of the head and neck: a clinicopathological study

    by E Montgomery, J R Goldblum, C Fisher

    Leiomyosarcoma of the head and neck: a clinicopathological study Aims: The behaviour of leiomyosarcoma is site‐related and there are few data on such tumours located in the head and neck. We studied the clinicopathological features of these lesions. Methods and results: Cases diagnosed as leiomyosarcoma of the head and neck were retrieved from the archives of three institutions. Immunohistochemistry was performed and follow‐up information was obtained. There were seven men and six women, aged 21–73 years, and lesions involved the neck (n=3), maxilla (n=4), buccal area (n=3), and maxillary sinus, nose, and pharynx (n=1 each). Tumours ranged from 10 to 80 mm. All tumours showed at least focally typical histological features of leiomyosarcoma with perpendicularly arranged fascicles of smooth muscle cells with blunt‐ended nuclei, eosinophilic cytoplasm and paranuclear vacuoles. They expressed muscle‐specific actin (8/9), smooth muscle actin (7/9), and desmin (10/12). Follow‐up information was available on nine patients. All had surgery, with radiation and/or chemotherapy in seven. Three (27%) recurred at 6–24 months; in one case twice. Five (56%) had metastases, including the three with prior recurrences at 1–128 months. Five (including two who received adjuvant therapy) were disease‐free at a median of 47 months, one was alive with metastatic disease at 24 months), and three were dead of disease (median 13 months). Conclusions: Head and neck leiomyosarcomas are rare and aggressive neoplasms which metastasize. Adjuvant therapy has limited effect.


  • Open Access

    Pathology of incipient neoplasia (3rd edition)

    by C Fisher

    The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

  • Leiomyosarcoma of the Paratesticular Region

    by Cyril Fisher, John R. Goldblum, Jonathan I. Epstein, Elizabeth Montgomery

    The behavior of leiomyosarcoma (LMS) is site related, but there are limited data on such tumors presenting in the paratesticular region. Cases diagnosed as LMS of the paratesticular region from the files of three institutions were reviewed. Immunohistochemistry was performed in cases with available blocks, and follow-up information was obtained. From 31 cases originally diagnosed as LMS, 24 were retained after review. These were from men aged 34-86 years (mean 62 years; median 64 years) and involved the testicular tunica (10), spermatic cord (10), scrotal subcutis and dartos muscles (1 each), and the epididymis (1). Tumors ranged in size from 2-9 cm (mean 5 cm; median 4 cm). On immunohistochemical staining they expressed muscle-specific actin (13 of 14), smooth muscle actin (10 of 10), desmin (16 of 17), and CD34 (3 of 9); all of the latter three were strongly desmin-positive. Focal reactivity for cytokeratin (3 of 8) and S-100 protein (1 of 8) was seen. Follow-up information was available in 14 patients. Four (29%) had recurrences, in one case four times. Metastases to lymph nodes, lungs, or liver were seen in four patients (29%), of whom two had prior recurrences. Ten were alive with no evidence of disease (ANED), and four were dead of disease (DOD). Comparing outcome with tumor grade, all seven patients with grade 1 tumors (of whom two had recurrences) and all three with grade 2 tumors were ANED, whereas all four patients with grade 3 tumors were DOD. In summary, paratesticular LMSs are rare neoplasms. The majority in this site are low-grade, although high-grade lesions behave aggressively.


  • Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study

    by E Montgomery, C Fisher

    Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study Aims: We compared the clinical and pathological features of pleomorphic malignant fibrous histiocytoma (MFH)‐like soft tissue sarcomas with and without myofibroblastic differentiation on electron microscopy. Methods and Results: Fifty‐three soft tissue tumours designated as MFH by light and electron microscopy were reassessed. Eighteen were specifically diagnosed and excluded, and follow‐up (FU) information obtained for 24 of the other 35 cases. Myofibroblastic ultrastructure was seen in 7/24 (29%). Seventeen of 24 (71%) lacked myofibroblasts on electron microscopy, which showed fibroblastic or undifferentiated cells. Histologically, all tumours but one had storiform‐pleomorphic areas; one myofibroblastic neoplasm was fascicular and myxoid. No other morphological differences were seen. In seven myofibroblastic cases, smooth muscle in four cases and muscle‐specific actin in two cases, desmin in three cases and S100 in one case were present. In 15 other tumours, smooth muscle in five cases and muscle‐specific actin in one case, and desmin in one case were present; none of these cases expressed S100. CD34 was found in the myxoid areas of one myofibrosarcoma and 3/15 other tumours. Positivity for bcl‐2 was seen only in non‐myofibroblastic sarcomas (4/14). On follow‐up (median 41 months), 2/7 (29%) myofibroblastic tumours recurred, 5/7 (71%) metastasized, and 3/7 (43%) patients died of disease. Among the non‐myofibroblastic sarcomas, with a median follow‐up of 47 months, 6/17 cases (35%) recurred, 10/17 (59%) metastasized, and 7/17 patients (41%) died of disease. Conclusions: Pleomorphic sarcomas with and without myofibroblastic differentiation on electron microscopy are clinically and histologically similar. The former display myoid immunohistochemical markers more frequently.